Acknowledgement
This research was supported by a grant from the Korea Health Technology R&B Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Korea (grant No.: HI22C0595).
References
- Skiada A, Pagano L, Groll A, Zimmerli S, Dupont B, Lagrou K, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect 2011;17:1859-67. https://doi.org/10.1111/j.1469-0691.2010.03456.x
- Alvarez E, Sutton DA, Cano J, Fothergill AW, Stchigel A, Rinaldi MG, et al. Spectrum of zygomycete species identified in clinically significant specimens in the United States. J Clin Microbiol 2009;47:1650-6. https://doi.org/10.1128/JCM.00036-09
- Schwartze VU, Hoffmann K, Nyilasi I, Papp T, Vagvolgyi C, de Hoog S, et al. Lichtheimia species exhibit differences in virulence potential. PLoS One 2012;7:e40908. https://doi.org/10.1371/journal.pone.0040908
- Pan J, Tsui C, Li M, Xiao K, de Hoog GS, Verweij PE, et al. First case of rhinocerebral mucormycosis caused by Lichtheimia ornata, with a review of Lichtheimia infections. Mycopathologia 2020;185:555-67. https://doi.org/10.1007/s11046-020-00451-y
- Chowdhary A, Gupta N, Wurster S, Kumar R, Mohabir JT, Tatavarthy S, et al. Multimodal analysis of the COVID-19-associated mucormycosis outbreak in Delhi, India indicates the convergence of clinical and environmental risk factors. Mycoses 2023;66:515-26. https://doi.org/10.1111/myc.13578
- Tissot F, Agrawal S, Pagano L, Petrikkos G, Groll AH, Skiada A, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica 2017;102:433-44. https://doi.org/10.3324/haematol.2016.152900
- CLSI. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. 3rd ed. M38-ED3. Wayne, PA: Clinical and Laboratory Standards Institute, 2017.
- CLSI. Interpretive criteria for identification of bacteria and fungi by targeted DNA sequencing. 2nd ed. MM18-ED2. Wayne, PA: Clinical and Laboratory Standards Institute; 2018.
- Alastruey-Izquierdo A, Cuesta I, Walther G, Cuenca-Estrella M, Rodriguez-Tudela JL. Antifungal susceptibility profile of human-pathogenic species of Lichtheimia. Antimicrob Agents Chemother 2010;54:3058-60. https://doi.org/10.1128/AAC.01270-09
- Subcommittee on antifungal susceptibility testing of the ESCMID. EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin Microbiol Infect 2008;14:982-4. https://doi.org/10.1111/j.1469-0691.2008.02086.x